BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Home
/
update
/
details

AdvancedDx Biological Laboratories and Complete Genomics Form Partnership for NGS-Based Infectious Disease Assays

NextEdge Admin

24 Sep 2024

1 min 13 sec

AdvancedDx Biological Laboratories,next-generation sequencing,partnership

AdvancedDx Biological Laboratories (ABL) has entered a co-marketing agreement with Complete Genomics to integrate and promote ABL’s microbiology assays with Complete Genomics' next-generation sequencing (NGS) technologies. While financial terms were not disclosed, the partnership aims to combine ABL's DeepChek assays and software with Complete Genomics’ DNBSeq sequencing platforms for the detection of infectious diseases such as HIV, viral hepatitis, respiratory viruses, and tuberculosis.

This collaboration will offer microbiology laboratories a wide array of NGS-based infectious disease assays using Complete Genomics' low-throughput sequencing platforms, including the DNBSeq-E25 and DNBSeq-G99. Radoje Drmanac, Founder and Chief Scientific Officer of Complete Genomics, expressed excitement about the partnership, noting that it will provide laboratories with enhanced diagnostic capabilities for infectious disease detection through advanced sequencing technology.